An investigation of toxicities and survival in Hispanic children and adolescents with ALL: Results from the Dana-Farber Cancer Institute ALL Consortium protocol 05-001

Hispanic children with ALL treated on DFCI 05-001 had significantly lower 5-year event-free survival and overall survival compared to non-Hispanic children, with ethnicity retaining significance for E

Effect: decline; 5-year EFS: 79.4% vs 87.5%, p=0.004; 5-year OS: 89.2% vs 92.7%, p=0.006; CI: EFS 95% CI: 71.6% to 85.2% (Hispanic) vs 84.5%-90.0% (non-Hispan

Hispanic patients aged 10 years and older treated for ALL on DFCI 05-001 had a significantly lower cumulative incidence of osteonecrosis compared to non-Hispanic patients, remaining significant in mul

Effect: improvement; HR 0.28; CI: 95% CI 0.10-0.76

Hispanic children under 10 years of age treated for ALL on DFCI 05-001 had a significantly lower cumulative incidence of bone fracture compared to non-Hispanic patients, remaining significant in multi

Effect: improvement; HR 0.24; CI: 95% CI 0.10-0.54

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

The overall incidence of post-induction asparaginase-associated toxicities including allergy, pancreatitis and thrombosis was not significantly different between Hispanic and non-Hispanic patients tre

Effect: null

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15